Comparing of VIVUS Inc. (VVUS) and Forward Pharma A/S (NASDAQ:FWP)

We are contrasting VIVUS Inc. (NASDAQ:VVUS) and Forward Pharma A/S (NASDAQ:FWP) on their risk, analyst recommendations, institutional ownership, profitability, dividends, earnings and valuation. They both are Biotechnology companies, competing one another.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
VIVUS Inc. 56.89M 0.98 42.52M -3.98 0.00
Forward Pharma A/S N/A 0.00 29.41M -0.28 0.00

Table 1 shows top-line revenue, earnings per share and valuation of the two companies.


Table 2 represents VIVUS Inc. (NASDAQ:VVUS) and Forward Pharma A/S (NASDAQ:FWP)’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
VIVUS Inc. -74.74% 182.8% -15.1%
Forward Pharma A/S 0.00% -7.8% -6.5%

Risk & Volatility

VIVUS Inc. has a 0.71 beta, while its volatility is 29.00% which is less volatile than Standard & Poor’s 500. Forward Pharma A/S’s 127.00% more volatile than Standard & Poor’s 500 which is a result of the 2.27 beta.


VIVUS Inc. has a Current Ratio of 4.4 and a Quick Ratio of 3.8. Competitively, Forward Pharma A/S’s Current Ratio is 17.2 and has 17.2 Quick Ratio. Forward Pharma A/S’s better ability to pay short and long-term obligations than VIVUS Inc.

Institutional & Insider Ownership

VIVUS Inc. and Forward Pharma A/S has shares held by institutional investors as follows: 18.3% and 18.8%. Insiders held 0.7% of VIVUS Inc. shares.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
VIVUS Inc. 3.53% -25.82% -37.79% -66.7% -52.05% -41.7%
Forward Pharma A/S -7.27% -40.35% -68.13% -63.31% -75% -72.28%

For the past year VIVUS Inc.’s stock price has smaller decline than Forward Pharma A/S.


Forward Pharma A/S beats on 5 of the 9 factors VIVUS Inc.

VIVUS, Inc., a biopharmaceutical company, develops and commercializes therapies to address unmet medical needs in the United States and the European Union. The company offers Qsymia for the treatment of obesity as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index of 30 or greater, or 27 or greater in the presence of at least one weight-related comorbidity, such as hypertension, type 2 diabetes mellitus or high cholesterol; and STENDRA, an oral phosphodiesterase type 5 inhibitor for the treatment of erectile dysfunction. It is also developing Qsymia, which has completed Phase II studies for the treatment of obstructive sleep apnea and diabetes, as well as for other obesity-related diseases, including nonalcoholic steatohepatitis, nonalcoholic fatty liver disease, hyperlipidemia, and hypertension. In addition, the company is developing Tacrolimus, which has completed Phase IIa studies for the treatment of pulmonary arterial hypertension. It has development, license and clinical trial, and commercial supply agreement with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of avanafil, a PDE5 inhibitor compound for the oral and local treatment of male and female sexual dysfunction. The company also has license and commercialization agreements with Berlin-Chemie AG and Auxilium Pharmaceuticals, Inc. to commercialize and promote STENDRA; and with Sanofi Winthrop Industrie to commercialize and promote avanafil. VIVUS, Inc. was founded in 1991 and is headquartered in Campbell, California.


Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.